Get the Stockscreener App
17.28
2.70%
-0.48
Oculis Holding Ag stock is traded at $17.28, with a volume of 13,174.
It is down -2.70% in the last 24 hours and up +0.70% over the past month.
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
See More
Previous Close:
$17.76
Open:
$18.125
24h Volume:
13,174
Relative Volume:
0.29
Market Cap:
$958.95M
Revenue:
-
Net Income/Loss:
$-75.28M
P/E Ratio:
-8.6586
EPS:
-1.9957
Net Cash Flow:
$-57.45M
1W Performance:
-6.19%
1M Performance:
+0.70%
6M Performance:
+17.47%
1Y Performance:
+42.11%
1-Day Range:
$17.25
$18.12
1-Week Range:
$17.25
$19.50
52-Week Range:
$10.79
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
17.28 | 958.95M | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.16 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.36 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
532.27 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.55 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
219.95 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-23 | Initiated | Chardan Capital Markets | Buy |
| Oct-05-23 | Initiated | Stifel | Buy |
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
View All
Oculis Holding Ag Stock (OCS) Latest News
HC Wainwright Weighs in on Oculis’ Q1 Earnings (NASDAQ:OCS) - Defense World
HC Wainwright Estimates Oculis’ Q2 Earnings (NASDAQ:OCS) - Defense World
Oculis (NASDAQ:OCS) Sees Large Volume Increase on Analyst Upgrade - Defense World
Oculis (NASDAQ:OCS) Price Target Raised to $33.00 - Defense World
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates - MSN
Oculis Announces 2025 Annual General Meeting Details - TipRanks
Oculis Publishes Invitation to the Annual General Meeting - The Manila Times
Dave To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Oculis Holding AG Reports Strong Q1 Progress - TipRanks
Learn to Evaluate (OCSAW) using the Charts - news.stocktradersdaily.com
Oculis Holding AG reports results for the quarter ended March 31Earnings Summary - TradingView
Oculis Holding AG Reports Q1 2025 Financial Results - TipRanks
Oculis Reports Q1 2025 Financial Results and Provides Company Update - The Manila Times
Earnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to Decline - Yahoo Finance
Oculis to Present at Upcoming May Investor Conferences - EIN News
REG-Oculis to Present at Upcoming May Investor Conferences - TradingView
Long Term Trading Analysis for (OCS) - news.stocktradersdaily.com
Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume – Still a Buy? - Defense World
Oculis Holding AG (NASDAQ:OCS) Shares Bought by Geode Capital Management LLC - Defense World
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences - The Manila Times
Oculis Holding AG to Present Innovative Late-Stage Pipeline at Major Ophthalmology Conferences in 2025 - Nasdaq
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences - GlobeNewswire Inc.
Oculis Holding AG to Present Innovative Late-Stage Pipeline at Major Ophthalmology Conferences in May 2025 - Nasdaq
Oculis Updates Share Capital - The Manila Times
Long Term Trading Analysis for (OCSAW) - news.stocktradersdaily.com
(OCS) Trading Advice - news.stocktradersdaily.com
Chardan Capital Reaffirms Buy Rating for Oculis (NASDAQ:OCS) - Defense World
HC Wainwright Increases Oculis (NASDAQ:OCS) Price Target to $32.00 - Defense World
Oculis (NASDAQ:OCS) Shares Gap Up Following Analyst Upgrade - Defense World
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award - The Manila Times
Stifel maintains Buy rating, $35 target on Oculis shares By Investing.com - Investing.com South Africa
Stifel maintains Buy rating, $35 target on Oculis shares - Investing.com
Oculis Holding AG Unveils Key Clinical Updates and Future Outlook at R&D Day - TipRanks
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets - The Manila Times
Oculis completes enrolment in trials for diabetic macular oedema eye drops - Yahoo
Oculis completes enrollment for pivotal DME treatment trials By Investing.com - Investing.com South Africa
Oculis Completes Enrollment in Late-Stage Diabetic Macular Edema Trials - marketscreener.com
Oculis completes enrollment for pivotal DME treatment trials - Investing.com
Oculis Wraps Up Patient Enrollment in Late-stage Studies of Topical Eye Drug - MarketScreener
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema - The Manila Times
REG-Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema - TradingView
(OCS) Trading Signals - news.stocktradersdaily.com
A First Look At Oculis Holding AG: Revenues Still Several Years Away (NASDAQ:OCS) - Seeking Alpha
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond - The Manila Times
Oculis Holding AG (NASDAQ:OCS) Short Interest Update - Defense World
Oculis Holding AG (NASDAQ:OCS) Short Interest Down 14.1% in February - Defense World
Oculis' Insider Moves: A Glimpse into the Company's Future? - AInvest
Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities - MarketScreener
Insider Buying: Oculis Holding Independent Director Bought CHF326k Of Shares - simplywall.st
Lionel Carnot Spends CHF326k On Oculis Holding Stock - Yahoo
Equities Analysts Set Expectations for Oculis Q1 Earnings - The AM Reporter
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):